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Abstract
Background: Jembrana disease virus (JDV) encodes a potent regulatory protein Tat that strongly
stimulates viral expression by transactivating the long terminal repeat (LTR) promoter. JDV Tat
(jTat) promotes the transcription from its own LTR as well as non-cognate LTRs, by recruiting host
transcription factors and facilitating transcriptional elongation. Here, we compared the sequence
requirements of jTat for transactivation of JDV, bovine immunodeficiency virus (BIV) and human
immunodeficiency virus (HIV) LTRs.
Results: In this study, we identified the minimal protein sequence for LTR activation using jTat
truncation mutants. We found that jTat N-terminal residues were indispensable for transactivating
the HIV LTR. In contrast, transactivation of BIV and JDV LTRs depended largely on an arginine-rich
motif and some flanking residues. Competitive inhibition assay and knockdown analysis showed
that P-TEFb was required for jTat-mediated LTR transactivation, and a mammalian two-hybrid
assay revealed the robust interaction of jTat with cyclin T1. In addition, HIV LTR transactivation
was largely affected by fusion protein at the jTat N-terminus despite the fact that the cyclin T1-
binding affinity was not altered. Furthermore, the jTat N-terminal sequence enabled HIV Tat to
transactivate BIV and JDV LTRs, suggesting the flexibility at the jTat N-terminus.
Conclusion: This study showed the distinct sequence requirements of jTat for HIV, BIV and JDV
LTR activation. Residues responsible for interaction with cyclin T1 and transactivation response
element are the key determinants for transactivation of its cognate LTR. N-terminal residues in jTat
may compensate for transactivation of the HIV LTR, based on the flexibility.
Background
Jembrana disease virus (JDV) is a bovine lentivirus that in
Bali cattle (Bos javanicus) often causes an acute disease
endemic in parts of Indonesia. After 5-12 days incubation,
infected cattle suffer clinical signs of fever and lymphade-
nopathy, with high viral titres of 108 infectious units per
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the JDV genome indicates that JDV is highly related to BIV
and HIV [4-6]. Generally, lentiviruses are associated with
chronic and progressive diseases involving a long period
of latent infection. Despite the high genomic similarity to
other lentiviruses, JDV infection shows an acute clinical
and pathological syndrome with a 20% fatality rate,
which is quite different from other milder lentiviruses
[6,7]. The most evident pathology of JDV infection is an
intense lymphoproliferative disorder affecting most organ
systems, including the enlarged lymph nodes and spleen,
as well as the proliferative lymphoid infiltrate in liver and
kidneys [3,8]. Recently, a tissue-derived vaccine has been
developed [9], and is currently used to control the spread
of Jembrana disease in Bali cattle. Vaccinated cattle were
found to have 96% reduction in viral load, indicating that
the vaccination may ameliorate the disease. Nevertheless,
little is known to date about the primary cause of acute
JDV pathogenesis.
A typical lentivirus genome is comprised of flanking long
terminal repeats (LTRs) and three major structural genes,
gag, pol, and env, as well as several accessory genes repre-
sented by small open reading frames (ORFs) in the central
and C-terminal regions [10]. Several lines of evidence
from the well-studied HIV-1 show that most accessory
genes are involved in viral replication and pathogenesis
[11-14]. Among the products of these accessory genes, the
transactivator of transcription (Tat) is the most important
for viral multiplication [15,16]. JDV Tat (jTat) also largely
contributes to rapid viral replication and establishment of
acute Jembrana disease [17-19]. JTat is encoded by two
exons derived from separate ORFs in the central RNA
genome with two potential splice donor (SD) sites at posi-
tions 5299 and 5335 and six potential splice acceptor (SA)
sites between nucleotides 4939 and 5007 [4,5,19].
Although the role of exon 2 is still unknown [18], jTat
exon 1 is a potent transactivator for viral gene expression
[18,20] and has been shown to modulate cellular gene
expression and induce apoptosis, based on our previous
studies [21,22]. Interestingly, jTat strongly transactivates
not only its own LTR but also the related BIV LTR and even
the primate HIV LTR, indicating that jTat has pleiotropic
functions [18,23]. Therefore, we assume that bovine len-
tiviruses have a close evolutionary relationship with pri-
mate lentiviruses and their Tat proteins share the
common roles in the viral life cycle, especially for LTR
activation.
Due to the unusual properties, several insights into jTat
function gradually emerged [24-27]. Much attention has
been paid to the jTat C-terminal RNA-binding domain
(RBD), particularly to the arginine-rich motif (ARM),
which confers capability of binding diverse species of
transactivation response element (TAR) [20,28-31]. An
earlier study demonstrates the chameleon-like property of
this 97 amino acid protein when binding to different TAR
targets [20]. Several studies report that the interaction of
jTat with the HIV TAR bulge is mediated by a single
arginine at position 70, which is a conserved residue
Arg52 in HIV Tat (hTat) [20,31-33]. In marked contrast,
the jTat RBD adopts the -hairpin conformation when
binding to BIV and JDV TARs [28,31,34]. Three conserved
arginines Arg70, Arg73 and Arg77 that are also present in
BIV Tat (bTat), and perhaps some other residues help sta-
bilize the -hairpin conformation. To achieve high RNA-
binding affinity, jTat folds to the correlative structures in
order to recognize the species-specific RNA architectures.
Structural analysis of the jTat/TAR complex has further
demonstrated that stabilization of the complex is medi-
ated by intermolecular RNA/protein contacts [31]. Taken
together, jTat RBD undergoes significant conformational
change when binding to different RNA targets, accounting
for its pleiotropic activities upon diverse LTR promoters.
The activation domain (AD) of Tat governs recruitment of
cellular transcription factors that antagonize the TAR-
induced repression of transcriptional elongation.
Recently, it has become clear that a cofactor of hTat is cyc-
lin T1 (CycT1), a component of the positive transcription
elongation factor b (P-TEFb) [35-38]. Tat/CycT1 het-
erodimer binds to TAR, allowing the cyclin-dependent
kinase 9 (CDK9) to modify the initiated RNA polymerase
II (pol II) transcription complex to a more elongation-
competent state, by phosphorylating the pol II C-terminal
domain (CTD) [39,40]. The machinery suggests that for-
mation of Tat/CycT1 is highly required for transactivation.
In addition, LTR transactivation requires that Tat/CycT1
heterodimer adopts a cooperative conformation to facili-
tate formation of Tat/CycT1/TAR ternary complex. For
instance, murine cells are non-permissive cells for hTat to
transactivate the HIV LTR. Although hTat is able to recruit
murine CycT1 (mCycT1), the resultant complex shows
weak affinity when binding to HIV TAR [41].
Unlike well-studied hTat, little is known about the iden-
tity and potential role of the jTat cofactor. The functional
domains in jTat by which transactivation of the cognate
and non-cognate LTRs is warranted remain unclear. In this
study, the minimal protein sequences (MPS) of jTat for
HIV, BIV and JDV LTR activation are investigated. We find
that HIV LTR transactivation by jTat requires the integrity
of jTat N-terminal domain (NTD), while activation of BIV
and JDV LTRs requires the ARM and the flanking residues.
Meanwhile, we demonstrate that CycT1 and CDK9 are
obligatory factors for JDV LTR activation as shown in com-
petitive inhibition assay and knockdown analysis. In vitro
and in vivo interaction studies reveal the robust interaction
of jTat with human, murine and bovine CycT1s. N-termi-
nal fusion protein largely affects the transactivation activ-
ity of jTat but does not alter the CycT1-binding affinity.
Furthermore, substitution of hTat N-terminal residuesPage 2 of 14
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nate LTR activities.
Results
Identification of the minimal protein sequence required for 
LTR activation
Previous studies demonstrate that jTat is a potent transac-
tivator of its own LTR as well as non-cognate LTRs, such as
HIV and BIV [42]. However, the jTat MPS required for LTR
transactivation is not clear. To identify the MPS, we gener-
ated a series of jTat mutants bearing the N-terminal and
the C-terminal truncations (Figure 1A). The truncation
mutant-stimulated HIV LTR activity in HeLa cells and BIV
and JDV LTR activities in BL12 cells were analyzed. The
preliminary experiments showed that all the LTRs
achieved the maximum activities when cells were trans-
fected with 50 ng pjTat (Figure 1B). The subsequent exper-
iments were performed using the same amount unless
specified.
By contrast with wild-type jTat, the N-terminal trunca-
tions from N20 to N40 stimulated less than 6% of LTR
activatities (Figure 1C). N5, N10 and N15 simulated 73%
to 86% of BIV and JDV LTR activities but less than 23% of
HIV LTR activity. These observations indicate that residues
downstream of N15 are indispensable for transactivation
of all three LTRs. The weak activation of HIV LTR by any
N5, N10 and N15 implies that HIV LTR transactivation
requires the integrity of jTat NTD.
C-terminal truncation mutants from C80 to C93 strongly
transactivated all three LTRs, whereas deletion of His80
(C79) abolished BIV and JDV LTR activities but not the
HIV LTR activity (Figure 1D). Truncation mutants from
C78 to C70 exhibited less than 17% of LTR activity by
wild-type jTat, suggesting that residues upstream of C78
are required for transactivating all three LTRs. Recent stud-
ies have addressed the key residues responsible for HIV
and BIV TAR binding [20,31]. In addition to three
arginines located in the jTat ARM, the His80 identified
here is a novel residue essential for jTat binding to BIV
TAR. Overall, the MPS responsible for HIV LTR transacti-
vation is amino acid residues 1-79 and that for BIV and
JDV LTR transactivation is 15-80.
The jTat RNA-binding domain contains the amino acid 
residues outside the jTat ARM
In vitro gel shift assays show that three arginines (Arg70,
73 and 77) in jTat are required for recognition of the BIV
and JDV TARs but Arg70 alone is sufficient for HIV TAR
recognition [20,31]. To further identify the key residues
for TAR binding in vivo, we fuse the putative jTat RBD in
different length to the competent hTat AD (Figure 2A).
The chimeric Tat, HJ69 and HJ70, showed the inability to
transactivate LTRs while HJ66, HJ67 and HJ68 fully sup-
ported LTR activation (Figure 2B), suggesting that the jTat
RBD includes Lys68 but not Arg66 or Arg67. These obser-
vations are consistent with an earlier finding that the
arginines outside the region 70-77 do not enhance TAR-
binding affinity [20]. By contrast with Arg66 and Arg67,
Lys68 is critical for LTR activation, suggesting that Lys68
probably contributes to formation of -hairpin conforma-
tion and/or recognizes the TAR bulge architecture.
To confirm the role of Arg70, Arg73, Arg77 and residues
78-81, we engineered several jTat mutants (Figure 2C).
The single-point mutants bearing R70K mutation fail to
transactivate HIV (Figure 2D), BIV and JDV LTRs (Figure
2F). By contrast, R7377K stimulated the attenuated HIV
LTR activity, (42% of the activity by wild-type jTat). It was
reported that JM1, in which the substitution of KIHY resi-
dues with bTat-derived RIRR was involved, showed weak
TAR-binding affinity [20]. Interestingly, the marked acti-
vation of all three LTRs by JM1 was observed in our exper-
iments (Figure 2D and 2F), suggesting that it is unlikely
that KIHY play an important role in functional TAR bind-
ing in vivo. HJ68 and BJ, two chimeric proteins containing
the jTat RBD (Figure 2E), exhibited stronger transactiva-
tion activity than wild-type hTat or bTat (Figure 2D and
Figure 2F). These results suggest the jTat possesses an
enhanced RBD, facilitating the higher TAR-binding affin-
ity. In addition, the JB chimeric protein simulated BIV and
JDV LTR activities in bovine cells (Figure 2F), indicating
that jTat residues 1-67 include the competent AD. Overall,
the jTat functional RBD is composed of a core region (res-
idues 70-77) as well as the flanking residues Lys68 and
His80.
LTR activation by jTat is enhanced by P-TEFb
In the case of HIV, Tat-mediated transcriptional elonga-
tion requires recruitment of P-TEFb to the LTR promoter
[38,40,43]. In this regard, Tat AD plays a role in recruiting
specific transcription factors. To test if P-TEFb is also
required for jTat-mediated transcription initiation and
elongation, we conducted the competitive inhibition
assays. Overexpression of hTat47 inhibited activation of
the HIV and JDV LTRs by their cognate Tats dose-depend-
ently (Figure 3A). Similar results were observed in the
competitive inhibition assays using overexpressed jTat67.
We reasoned that the excessive hTat AD sequestered P-
TEFb which also participated in the jTat-mediated LTR
transactivation, leading to the consequent inhibition. Our
findings demonstrate that hTat and jTat recruit the com-
mon transcription factors for LTR transactivation.
P-TEFb consists of CycT1 and CDK9, which is also known
as PITALRE, a 43-kDa protein protein kinase that phos-
phorylates the pol II CTD [44,45]. To investigate their role
in LTR activation, we employed the CycT1 and CDK9 anti-
sense plasmids in HeLa cells to deplete endogenous fac-
tors. The effect of rT1 and rCDK9 on the correlative CycT1
and CDK9 expression was monitored by semi-quantita-Page 3 of 14
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Activation of LTR reporters by wild-type jTat or truncation mutantsFigure 1
Activation of LTR reporters by wild-type jTat or truncation mutants. (A) Schematic representation of N-terminal 
(upper) and C-terminal (lower) truncation mutants. Numbers indicate the residue positions. (B) Cells were co-transfected with 
25 ng LTR-luc reporter, 50 ng pCMV-LacZ and the indicated amounts of wild-type jTat expression plasmid (pjTat). Total DNA 
was adjusted to equivalent amounts with pcDNA3.1(-). Luciferase activity was measured 48 h post transfection and normalized 
to -galactosidase activity. Asterisk marks the optimal pjTat levels, which are used in subsequent assays. (C) HIV LTR activation 
in HeLa cells and BIV or JDV LTR activation in BL12 cells by jTat wild-type (WT) or N-terminal truncation mutants. (D) LTR 
activation by WT or C-terminal truncation mutants. WT activity on each reporter is set to 100% and percentage activation is 
the relative activity of the indicated mutant. Error bars represent the standard deviation from the mean obtained from more 
than three independent experiments.
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jTat RBD residues critical for functionFigure 2
jTat RBD residues critical for function. (A) Schematic representation of the sequence near the RBD of hTat and jTat 
(upper) and chimeric proteins bearing hTat AD and jTat RBD (lower). Shaded characters indicate residues evaluated by dele-
tion analysis. hTat AD; hTat residues 1-47. (B) Percentages of LTR activation by different chimeric Tat proteins are shown and 
those by HJ66 are set to 100%. (C) Sequence alignment among jTat, bTat and three mutants. Boxed bold characters indicate 
residues differing from wild-type jTat. (D) Activities of mutant and wild-type jTat proteins, bTat and hTat on the HIV LTR 
reporter in HeLa cells. jTat activity is set to 100%. (E) Schematic representation of chimeric proteins bearing either bTat AD 
and jTat RBD (BJ) or jTat AD and bTat RBD (JB). (F) Activities of mutant jTat proteins, chimeric proteins, and wild-type bTat 
and jTat proteins on BIV LTR and JDV LTR reporters in BL12 cells. jTat activity is set to 100%. The dotted line in (A) and (E) 
indicates where the proteins are fused.
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Requirement for P-TEFb in LTR activation by jTatFig re 3
Requirement for P-TEFb in LTR activation by jTat. (A) Competitive inhibition assays. HeLa cells (upper graphs) were 
co-transfected with 50 ng hTat, 25 ng pHIV-LTR-luc, 50 ng pCMV-lacZ and indicated amounts of hTat47 (left) or jTat67 (right). 
Similar experiments were performed in BL12 cells using pjTat and pJDV-LTR-luc instead of hTat and pHIV-LTR-luc. hTat47; 
hTat residues 1-47. jTat67; jTat residues 1-67. (B) HIV LTR activation by jTat in HeLa cells with depleted hCycT1 or CDK9. 
HeLa cells were transfected with indicated amounts of antisense plasmids against hCycT1 (rT1) or CDK9 (rCDK9) and tested 
for jTat activity on the HIV LTR reporter. Western analysis shows dose-dependent effect of antisense plasmids on expression 
of exogenous Flag-hCycT1 or Flag-CDK9 (see Methods for experimental protocol). Total protein levels in the western analysis 
were equivalent.
Virology Journal 2009, 6:179 http://www.virologyj.com/content/6/1/179tive western-blotting analysis as described in Methods. We
found that HIV LTR activation by jTat decreased as did lev-
els of endogenous CycT1 or CDK9 (Figure 3B), whereas
no such decrease was observed in LTR basal transcription
activity (data not shown). These data suggest LTR activa-
tion by jTat is dependent on both CycT1 and CDK9.
The jTat-binding component in P-TEFb is CycT1, not 
CDK9
The correlation between LTR activation and P-TEFb
recruitment indicates that components of P-TEFb may
bind jTat. To test this possibility, we first analyzed the
interactions of jTat with human CycT1 (hCycT1), bovine
CycT1 (bCycT1) and mCycT1. In vitro GST pull-down
assays showed that both GST-hTat (Figure 4A, Lane 3) and
GST-jTat (Figure 4A, Lane 4) could interact with all
CycT1s tested. As a control, GST did not bind any CycT1
species (Figure 4A, Lane 2). To further investigate the
interactions in vivo, we evaluated diverse Tat proteins and
potential interaction partners in a mammalian two-
hybrid system (Figure 4B). Tats were fused to the C-termi-
nus of NF-B AD, facilitating exposure of their N-termini,
and transcription factor candidates were fused to GAL4
BD. HeLa cells were co-transfected with AD plasmid, BD
plasmid and the pFR-luc reporter. The interactions in vivo
were assayed by monitoring luciferase activity. JTat could
interact directly with all CycT1s tested but not CDK9 (Fig-
ure 4C). Notably, the highest luciferase activity was
obtained from the interaction of jTat with bCycT1, which
was two- to three-fold of the activity from the interaction
of hTat with hCycT1. Interestingly, we identified human
CycT2b, a CDK9 cyclin not bound by hTat [46], as
another jTat-associated cyclin in this experiment (Figure
4C).
Although jTat shows high CycT1 affinity, we ask whether
the resultant heterodimer could bind to TAR element and
activate the LTR, particularly given that hTat/mCycT1 het-
erodimer cannot activate the HIV LTR [41]. We compared
the HIV LTR activities in murine cells when stimulated by
jTat, HJ68 and hTat. Similar to hTat, HJ68 that harbored
the jTat RBD showed inability in 3T3 cells (Figure 4D).
However, LTR activity was fully restored when cells were
supplemented with hCycT1. By contrast with HJ68, jTat
showed the potent transactivation ability in an hCycT1-
independent manner (Figure 4D), indicating the jTat/
mCycT1 heterodimer could bind to TAR in murine cells.
The CycT1-binding sequence confers transactivation 
activities on BIV and JDV LTRs but not on the HIV LTR
To further investigate the key residues for CycT1 binding,
we constructed several jTat mutants (Figure 4B) to test the
potential interactions with their preferred bCycT1. A sin-
gle-point mutants bearing C38S mutation in the jTat AD
showed the attenuated bCycT1-binding affinity (Figure
5A). Cysteines in Tat contribute to formation of a metal-
linked complex [47]. Our studies support the hypothesis
that the jTat AD binds to a metal ion near the CycT1-bind-
ing interface, employing Cys38 as a metal ligand. By con-
trast with C38S, the R70K mutation did not affect the
bCycT1-binding affinity. Furthermore, equivalent
bCycT1-binding affinity was detected for wild-type jTat,
the jTat AD and the chimeric JH (Figure 5A). However,
two truncation mutants lacking residues 62-67 were una-
ble to interact with bCycT1, suggesting that the jTat AD
includes these residues. To further confirm the MPS of jTat
AD, we subcloned the N-terminal truncation mutants to
the mammalian two-hybrid AD vector. Interaction analy-
sis showed that residues downstream of N15 were
required for jTat binding to hCycT1, bCycT1 and mCycT1
(Figure 5B). Despite an essential role in the HIV LTR trans-
activation (Figure 1C), residues 1-14 are not required for
CycT1 binding irrespective of CycT1 species. Hence, jTat
15-67 is sufficient to function as a CycT1-binding domain
but not as an AD to transactivate the HIV LTR.
JDV Tat shows apparent flexibility at its N-terminus
To further examine the function of N-terminal sequence,
we constructed the recombination plasmids expressing
Tat-fusion protein at either the N- or C-terminus (Figure
6A). HIV LTR activity in HeLa cells and JDV LTR activity in
BL12 cells were analyzed for these recombined Tats,
respectively (Figure 6B). Activities above 60% and below
20% of the wild-type jTat-induced LTR activation were
defined as the high and low levels, respectively (Figure 6B,
dashed lines). Fusion proteins at the C-terminus stimu-
lated the moderate JDV LTR activities, similar to hTat-
mediated HIV LTR activation. By contrast, N-terminal
fusions severely impaired the transactivation of the HIV
LTR. This observation suggests that the N-terminal
sequence must be exposed to support HIV LTR activation.
Interestingly, similar results were observed for hTat (Fig-
ure 6B).
To determine whether the low CycT1-binding affinity
accounted for the weak LTR transactivation by jTat with N-
terminal fusions, we subsequently determined the affin-
ity. With GAL4 BD at the jTat N-terminus, BD-J exhibited
strong interaction with hCycT1 and bCycT1, similar to J-
NFB which contained fusion protein at C-terminus (Fig-
ure 6C). These results demonstrate that the CycT1 affinity
is not altered by blocking the N-terminus, thus excluding
the possibility that weak HIV LTR activation is due to the
failure to recruit CycT1.
Next we replaced hTat and bTat N-terminal residues with
those of jTat, producing jN21-hTat and jN17-bTat chi-
meric proteins (Figure 6D). We used both chimeras to
challenge wild-type jTat in transactivating the HIV, BIV
and JDV LTRs. JN21-hTat stimulated significant transcrip-Page 7 of 14
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Interaction of jTat with CycT1 in vitro and in vivoFigure 4
Interaction of jTat with CycT1 in vitro and in vivo. (A) Interaction of hTat and jTat with mammalian CycT1s. GST and 
GST-tagged proteins were immobilized on beads and incubated with the cell lysates as described in Methods. The pull-down 
complexes and 5% of cell lysate input were analyzed by western-blotting using anti-Flag antibody. The coomassie blue staining 
shows 10% of the amounts of the purified proteins utilized in this experiment. Numbers mark the molecular weight standards 
(MW). (B) Schematic representation of mammalian two-hybrid constructs. jAD; jTat residues 1-67. JH; jTat 1-67 fused to hTat 
48-72. (C) HeLa cells were co-transfected with 500 ng J-NFB or H-NFB, 500 ng of the indicated Gal4 BD plasmid and 250 ng 
pFR-luc. Fold-induction shows the relative activity of pFR-luc reporter and reflects binding affinity between Tat and its cofactor. 
(D) HIV LTR activation in 3T3 cells by indicated Tats in the absence or presence of hCycT1. The amount of transfected pCMV-
Tag2B-hCycT1 was 50 ng. T1; Cyclin T1 residues 1-272.
Virology Journal 2009, 6:179 http://www.virologyj.com/content/6/1/179tional activation of all three LTRs (above 60% of the activ-
ity by jTat), suggesting that N-terminal sequence may
enable formation of the heterologous hTat/bCycT1/JDV
(BIV) TAR ternary complex (Figure 6E. c). Unlike jN21-
hTat, jN17-bTat could only transactivate BIV and JDV
LTRs but not the HIV LTR (Figure 6D and Figure 6E. d).
Overall, our results suggest that jTat N-terminus displays
high flexibility, which in turn facilitates multi-functional
activities of jTat on the cognate and non-cognate LTRs.
Discussion
Acute Jembrana disease by JDV is partially caused by a
potent transactivator encoded by the accessory gene tat.
Here, we demonstrate the minimal sequence requirement
for jTat function and reveal flexibility of its N-terminal
domain. We have characterized the functional RBD of jTat
responsible for transactivation of HIV (residues 68-79),
BIV and JDV LTRs (residues 68-80) (Figure 1 and 2). Post-
translational modifications such as phosphorylation,
methylation, acetylation, ubiquitinylation and SUMOyla-
tion affect protein structure. For example, the appreciation
that hTat acetylation is biologically relevant has increased
in recent years [48-50]. In particular, hTat is acetylated at
Lys50 by p300, which possesses intrinsic histone acetyl-
transferase (HAT) activity [49,51], leading to Tat and
p300 synergy in HIV transcription. Aceylation of Lys28 by
p300/CBP-associated factor (PCAF) is also essential for
HIV-1 replication, likely by enhancing affinity and stabil-
ity of the Tat/CycT1/TAR ternary complex [50,52]. We
show that deletion of the jTat Lys68, which is conserved
as the hTat Lys50, abolished transactivation of all three
LTRs (Figure 2B). Lys68 and possibly Lys69 are likely
acetyl-acceptors that contribute to TAR-binding affinity
and consequently to transcriptional activation. His80 is
also required for jTat-mediated transactivation of BIV and
JDV LTRs. Given that a single arginine at position 52 in
hTat fully mediates interaction with the HIV TAR bulge,
several studies on the jTat RBD propose that residues near
the jTat ARM other than Arg70, Arg73 and Arg77 act as a
scaffold upon TAR recognition, promoting complex stabi-
lization [20,31]. Our findings imply that His80 may be
critical for the scaffold (Figure 1D).
In response to viral infections, host cells have evolved
strategies to inhibit viral replication, while viruses have
co-evolved mechanisms to counteract inhibitions and
jTat residues essential for the interaction with CycT1Figu e 5
jTat residues essential for the interaction with CycT1. (A) HeLa cells were cotransfected with BD-bT1, the indicated 
Tat-NFB fusion plasmid (detailed in Fig. 4B), and pFR-luc. Induced activation of pFR-luc reporter by wild-type jTat is set to 
100%. Percent induction by jTat mutants is shown. The interaction partner utilized in this experiment is bCycT1. (B) The role 
of jTat N-terminal residues in CycT1 binding. Binding affinities are measured between jTat N-terminal truncation mutants and 
different CycT1 species.Page 9 of 14
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Flexible properties of the jTat N terminusigur 6
Flexible properties of the jTat N terminus. (A) Schematic representation of fusion proteins tagged at the jTat N- or C-
terminus. (B) LTR activation in permissive cells by wild-type jTat (set to 100%) or jTat with a fusion at either terminus. Dashed 
lines mark 20% (lower line) and 60% (upper line). (C) Comparison of hCycT1 or bovine bCycT1 affinity between jTat with N- 
or C-terminal fusions. BD-J; Gal4 BD at the jTat N terminus. (D) HIV, BIV and JDV LTR activites stimulated by two chimeric 
Tat proteins, jN17-bTat and jN21-hTat(upper panel), and wild-type jTat (set to 100%). Boxed residues represent wild-type 
jTat. (E) Possible structures of the Tat/CycT1/TAR ternary complexes. TAR RNA secondary structure includes stalk, bulge and 
loop. The compositions of the ternary complexes are listed below.
Virology Journal 2009, 6:179 http://www.virologyj.com/content/6/1/179even co-opt cellular factors to serve as co-factors. Like
other lentiviruses, JDV recruits P-TEFb, which phosphor-
ylates the pol II CTD to initiate transcriptional elongation.
Our studies identify a physical interaction between CycT1
and jTat residues (Figure 4). Alignment of JDV, BIV, HIV-
1, and HIV-2 Tat proteins shows that jTat has a conserved
cysteine-rich domain (CRD), which may contribute to the
binding of CycT1. C38S mutation within the jTat CRD
produced a CycT1-binding-incompetent mutant (Figure
5A), suggesting that the interaction of jTat with CycT1
involves a metal ion near the binding interface and that
Cys38 may act as a metal ligand. In previous studies, sim-
ilar requirements of seven cysteines in hTat and one
cysteine in hCycT1 (Cys261) were proposed to bridge
interactions among hTat, hCycT1 and the HIV TAR
[47,53,54]. Those observations lead us to ask whether the
hCycT1 critical cysteine is the metal ligand required for
jTat/CycT1/TAR ternary complex formation. However,
our results showed that jTat could transactivate the HIV
LTR in murine cells (Figure 4D), harboring the mCycT1
which lacks this cysteine. Thus, it is unlikely that Cys261,
the critical cysteine in hCycT1 for hTat function, partici-
pates in formation of metal-bridged jTat/CycT1/TAR ter-
nary complex. Clearly, the mechanism of the metal-
ligand-mediated interaction employed by jTat needs fur-
ther examination.
The flexibility of the jTat N-terminus is a highly significant
finding. Although the jTat AD for the BIV and JDV LTRs
(residues 15-67) can be perfectly represented by the
CycT1-binding domain of jTat, a candidate jTat AD for
HIV LTR (residues 1-67) is different from the CycT1-bind-
ing domain (Figure 1, 2 and 5). This interesting finding
emphasizes the important role of N-terminal sequence 1-
14 in formation of jTat/hCycT1/HIV TAR and conse-
quently the transcriptional activation of the HIV LTR. We
have noted that hTat/mCycT1 is not recognized by the
HIV TAR, suggesting that strong LTR activation requires
cooperative interactions occurring in the Tat/CycT1/TAR
ternary complex. Thereby, jTat 1-14 likely establish a TAR-
binding-competent state for jTat/CycT1 heterodimer,
despite the fact that deletion of these residues does not
alter CycT1-binding affinity (Figure 5B).
We also found that jTat N-terminal fusion proteins
severely attenuate its transactivation activity, especially for
the HIV LTR (Figure 6B). However, since N-terminal
fusions still bind CycT1 (Figure 6C), this observation sug-
gests that other structural motifs are required for function.
The region encompassing N-terminal residues 1-14 could
comprise a domain promoting formation of a ternary
complex. The jTat N-terminus is a glycine-rich region
(GRR) which in other proteins shows diverse biological
functions [55-57]. The jN21-hTat GRR enabled activities
on the cognate and non-cognate LTR reporters (Figure
6D). It is well-known that hTat possesses a relatively weak
TAR-binding ARM peptide that adopts an extended con-
formation when bound to HIV TAR but causes stacking
between two helical stems and formation of a U-A:U base
triple in TAR RNA [35,58]. In addition, CycT1 inserts into
the TAR loop, further stabilizing the ternary complex (Fig-
ure 6E. a). However, the weak ARM alone cannot stabilize
hTat/bCycT1/JDV TAR complex without bCycT1 inserted
to the loop (Figure 6E. b). The fact that jN21-hTat transac-
tivates the JDV LTR suggests that the jN21-hTat GRR likely
induce contact between bCycT1 and the JDV TAR (Figure
6E. c), producing a stabler ternary complex competent to
recruit CDK9, allowing transcriptional elongation to
occur. In the case of BIV Tat, a -hairpin structure is
formed following a large conformational rearrangement
in the ARM when bound to BIV TAR, promoting specific
contacts to TAR RNA [34,59]. Given that jN17-bTat does
not activate the HIV LTR reporter, we propose that jN17-
bTat, which contains the same ARM as bTat, cannot adopt
the proper -hairpin conformation to recognize the HIV
TAR (Figure 6E. d). These questions should be addressed
in further structural studies.
Conclusion
Our investigation of key residues in jTat reveals two dis-
tinct patterns when jTat activates a primate LTR versus
cognate LTRs. We conclude that residues 1-67 in jTat func-
tion as the AD for the HIV LTR, while residues 15-67 com-
prise the AD for the BIV and JDV LTRs (Figure 7). Cys38
of jTat contributes to CycT1 binding and consequently to
activation of all three LTRs. We also find that Lys68 plays
an essential role in the RBD, in addition to arginines at
positions 70, 73 and 77. Lys68 and perhaps Lys69 are
potential acetyl-acceptors. In addition, His80 participates
in jTat-mediated transactivation but only in bovine mod-
els. Finally, we find that the jTat N-terminus endows the
protein with multi-transactivation activities on lentivirus
LTR promoters. Our results provide novel insight into this




To generate the eukaryotic expression plasmid pjTat, JDV
Tat exon 1 coding sequence was amplified from the JDV
clone 147 [4] via PCR by using the forward primer 5' GGC
CTC GAG ATG CCT GGT CCC TG 3' and the reverse
primer 5' GCT CGA ATT CAA CGA TCT AGT G 3'. The
product was digested with Xho I and EcoR I and inserted to
the same sites of pcDNA3.1 (-) vector (Invitrogen). Con-
structs of HIV Tat exon 1 and BIV Tat exon 1 were gener-
ated from their proviral clones pNL4-3 and pBIV127,
respectively. HIV, BIV and JDV LTRs were provided by
Charles Wood (University of Nebraska Lincoln), sub-
cloned to pGL3-basic luciferase reporter vector (Promega)Page 11 of 14
(page number not for citation purposes)
Virology Journal 2009, 6:179 http://www.virologyj.com/content/6/1/179and placed upstream of luc gene. The full-length CDK9,
human cyclin T2 isoform B (CycT2b) and residues 1-272
of human, bovine and murine CycT1, were kind gifts from
Alan Frankel (University of California, San Francisco) and
subcloned to pcDNA3.1 (+) and pCMV-Tag2B vectors
(Stratagene). The plasmids expressing Tat chimeric pro-
teins were constructed by combination of functional
domains from Tat, NF-B, GALl4, EGFP. The pjN21-hTat
and pjN17-bTat plasmids were produced by replacing
hTat and bTat 5' coding sequences with indicated jTat cod-
ing sequences (Figure 6D).
Cell culture
HeLa, HEK 293T, NIH 3T3 and the bovine lung BL12 cell
line [60] were cultured in Dulbecco's modified Eagle's
medium (GIBCO) supplemented with 10% fetal bovine
serum (FBS), 50 IU/ml penicillin and 50 g/ml streptomy-
cin at 37°C in humidified air with 5% CO2.
Mutagenesis
The pjTat plasmid was used as the starting material when
mutagenesis was done. The sequence coding jTat N-termi-
nal and C-terminal truncation mutants were PCR ampli-
fied by using specific primers. The single-point and
multiple-point mutants were generated by overlapping
PCR methodology as described elsewhere [61]. All PCR
products were cloned into vector pcDNA3.1 (-), produc-
ing several constructs shown in Results (Figure 1A and Fig-
ure 2C). The sequences of all constructs were confirmed
by sequencing. Primers used for cloning and mutagenesis
are available on request.
Transient transfection and luciferase reporter assay
Transient transfection was carried out in a 12-well plate.
About 1 × 105 HeLa cells or 1.5 × 105 BL12 cells were
seeded in each well and transfection was always per-
formed 24 h after seeding. The transfection system con-
tained 25 ng pLTR-luc reporter, 50 ng Tat eukaryotic
expression plasmid and 50 ng pCMV-lacZ. Total amounts
of DNA were equalized by adding the vector DNA. The
transfection system was mixed with 2 g LipofectAMINE
(GIBCO-BRL) and then added to cells. Prior to addition,
cells were washed twice and maintained in DMEM with-
out FBS. Fresh DMEM with 20% FBS was supplemented to
cells 8 h post transfection. Cells were harvested 48 h post
transfection, and luciferase activity was determined fol-
lowing the manufacture's instruction (Promega) and nor-
malized to the -galactosidase activity. Each experiment
was done at least three times independently.
CDK9 and CycT1 knockdown
The coding sequences of human CycT1 and CDK9 were
subcloned to pcDNA3.1 (-) in the antisense orientation,
producing the antisense plasmids rT1 and rCDK9. Deple-
tion of hCycT1 and CDK9 was confirmed by semi-quanti-
tative western-blotting analysis 48 h after HeLa cells were
co-transfected with 50 ng pCMV-Tag2B-hCycT1 or pCMV-
Tag2B-CDK9 along with 50, 100, 500, or 1000 ng rT1 or
rCDK9 plasmid, respectively. Total DNA amount used for
each transfection was kept constant by adjusting with
pcDNA3.1 (-). After transfection, equivalent cell lysates
were immunoblotted with anti-Flag antibody to assess the
expression of Flag-hCycT1 and Flag-CDK9. The level of -
actin was also determined as an internal control. Anti-Flag
M2 monoclonal antibody (MAb) and secondary HRP-
conjugated antibody were purchased from Santa Cruz
Biotechnology and anti--actin MAb were purchased from
Sigma-Aldrich.
GST-pulldown assay
For GST-pulldown assay in vitro, GST, GST-jTat and GST-
hTat fusion protein were immobilized on glutathione
sepharose beads (GE Healthcare) and incubated with the
following cell lysates. HEK 293T cells were cultured in
Schematics of the full-length jTat and its functional domainsFigure 7
Schematics of the full-length jTat and its functional domains. Activation and RNA-binding domains responsible for 
transactivating HIV, BIV, and JDV LTRs are shown. Key residues contributing to jTat function are dotted in bold. Numbers indi-
cate the residue positions. NTD; N-terminal domain. CRD; cysteine-rich domain. Core; core domain. Basic; basic amino acid-
rich domain. CTD; C-terminal domain.Page 12 of 14
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2 g of pFlag-CycT1. Cells were harvested 36 h post trans-
fection, washed twice with phosphate-buffered saline
(PBS) and lysed with 20 mM Tris pH 8.0, 100 mM NaCl,
5 mM MgCl2, 0.5% Nonidet P-40, 1 mM EDTA and 1×
protease inhibitor cocktail (Sigma-Aldrich). After the
lyastes was centrifuged at 10,000 × g for 15 min at 4°C,
the supernatant were precleared with fresh glutathione
sepharose beads to eliminate any contaminant prior to
incubation with the GST-saturated beads. After 2 h incu-
bation at 4°C, beads were washed with the lysis buffer to
eliminate any unspecific binding, and then boiled in 40 l
of 1× Laemmli buffer. Samples were electrophoresed on
12% SDS-polyacrylamide gel and subjected to western-
blotting.
Mammalian two-hybrid assay
In this assay, various Tats of interest were fused to the N-
terminus of the transcriptional activation domain of the
mouse protein NF-B. A set of transcription factors, which
were candidates for potential interaction partners, were
fused to the DNA-binding domain of the yeast protein
GAL4. If an interaction occurs, they create a functional
transcription activator by bringing the NF-B AD into
close proximity with GAL4 BD which can be detected by
expression of the luciferase reporter gene. HeLa cells were
co-transfected 500 ng NF-B AD plasmid, 500 ng GAL4
BD plasmid and 250 ng pFR-luc reporter (Stratagene).
Each assay was performed more than three times.
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